Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors
Jiaming Shen,Xia Wang,Guangde Yang,Li Li,Juanjuan Fu,Wei Xu,Qingqiao Zhang,Xiucheng Pan
DOI: https://doi.org/10.2147/jhc.s431191
2024-01-25
Journal of Hepatocellular Carcinoma
Abstract:Jiaming Shen, 1, 2, &ast Xia Wang, 2, &ast Guangde Yang, 2, &ast Li Li, 2 Juanjuan Fu, 2 Wei Xu, 3 Qingqiao Zhang, 3 Xiucheng Pan 2 1 Department of Gastroenterology, People's Hospital of Jingjiang, Taizhou, People's Republic of China; 2 Department of Infectious Disease, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China; 3 Department of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiucheng Pan, Tel +8618052268129, Email Purpose: Recently, the triple therapy of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs) has become a new treatment option for advanced or unresectable hepatocellular carcinoma (HCC) patients. We aimed to explore the liver injury and its effect on overall survival (OS) in patients treated with this combination therapy. Patients and Methods: Patients with HBV-related HCC who were treated with TACE-TKIs-ICIs from January 2020 to December 2021 were enrolled. Liver injury and survival time were the main endpoints of the study. Logistic regression analysis was used to analyze the factors associated with liver injury. Cox regression and Kaplan–Meier analysis were used to determine prognostic factors for OS. Results: As of March 2022, 52 of the 119 enrolled patients developed any grade hepatotoxicity: 15 cases with grade 1, 19 cases with grade 2, 16 cases with grade 3 and 2 cases with grade 4. Our analysis indicated that lack of antiviral prevention was a risk factor for liver injury (OR = 0.149; 95% CI: 0.050– 0.442; P = 0.001). The findings suggested that liver injury events (HR = 1.912; 95% CI: 1.031– 3.546; P = 0.040) was associated with patient death. The median OS of patients without liver injury, grade 1– 2 and grade 3– 4 liver injury were undefined, 13.7 months and 11.1 months, respectively (log-rank P = 0.034). Conclusion: Liver injury adverse events are common in HBV-related HCC patients treated with TACE-TKIs-ICIs. Patients who developed liver injury had a poor prognosis. For HBV-related HCC patients, effective prophylactic antiviral therapy and regular liver function testing are required before and during this triple therapy. Keywords: HBV-related HCC, TACE, TKI, ICI, liver injury, survival time Graphical Primary liver cancer is one of the most common cancers in the world, of which hepatocellular carcinoma (HCC) accounts for the vast majority. 1 HBV infection is a major risk factor for HCC, especially in most Asian countries and regions. 2 Despite improvements in monitoring and treatment of hepatitis B, many HCC patients are firstly diagnosed with unresectable or advanced stage, which is not suitable for early radical treatment and has a poor prognosis. Transarterial chemoembolization (TACE) is commonly recommended by various guidelines for local treatment of intermediate-stage or unresectable HCC. 3–5 However, repeated TACE treatment may damage liver function, and embolism-induced hypoxia can lead to expression of vascular endothelial growth factor and promote tumor recurrence and metastasis. 6 Tyrosine kinase inhibitors (TKIs), such as sorafenib, lenvatinib and apatinib, can reduce tumor angiogenesis by inhibiting vascular endothelial growth factor receptor. 7 In this setting, TACE combined with TKI has synergistic anticancer effect and improves the prognosis of patients with advanced HCC. 6,8,9 The combination of TKI and ICI such as "atezolizumab-bevacizumab" regimen has been recommended as the first-line therapy for patients with unresectable or advanced HCC because of its remarkable efficacy. 10,11 Since TACE can cause tumor tissue necrosis and activate tumor-specific immune responses, 12 the triple therapy of TACE combined with TKIs plus ICIs has become a new treatment option for patients with advanced or unresectable HCC in recent years. However, previous studies have found that TACE alone, single TKI agent or immunotherapy may lead to hepatic adverse events. 13–15 A systematic review reported that the incidence of elevated liver enzymes after TACE therapy was 52% in HCC patients. 15 Griffiths et al 16 summarized that the incidence of hepatotoxicity under ICIs or TKIs treatment in advanced HCC patients was 28% and 21%, respectively. In LAUNCH prospective trial, the incidence of liver injury in advanced HCC patients treated with TACE and lenvatin -Abstract Truncated-
oncology